NCT06146816Recruiting
The Assessment of Infrared Treatment for Crohn's Disease
An Exploratory Clinical Trial for the Assessment of Infrared Treatment for Crohn's Disease
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients. The main questions it aims to answer are: 1. Is infrared therapy safe for treating Crohn's disease patients? 2. Is infrared therapy effective for treating Crohn's disease? Participants will be asked to attend 10 treatments of fIR therapy, provide stool and blood samples and answer questionnaires. Researchers will compare between 4 treatments: three intensities of fIR therapy and placebo treatment to explore which intensity is most effective for treating Crohn's disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 19 Nov 2023
- Start date
- 12 Sept 2023
- Primary completion date
- Sept 2027
- Lead sponsor
- Shmuel Kivity, MD
- Diseases
- Crohn's disease
- NCT number
- NCT06146816
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 12 Sept 2023 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- More than one CD luminal surgery or a small bowel length \< 1.5 meter
Other illness
- Any proven current infection such as Clostridioides difficile infection, positive stool culture, or parasites.
- Subjects with chronic conditions such as cancer, organ transplant subjects, advanced kidney or liver disease, systemic inflammatory conditions other than IBD.
- Evidence of an abdominal abscess or entero-enteric fistula.
Other
- BMI greater than 30 Kg/m2
- Inability to sign informed consent and complete study protocol
- Pregnancy
- Presence of abscess and cysts in the liver/ kidneys or pancreas
Who the study is looking for
- An established Crohn's disease
- 18 \< age \< 80
- No therapy or on constant medicinal regimen throughout the study period: mesalamine at least 6 weeks, or steroids at least 2 weeks, or immunomodulatory drugs at least 12 weeks or biologics at least 12 weeks, medical cannabis at least 2 weeks before the study.
- CD patients will be included if their symptoms score \>4 on the Harvey-Bradshaw index (HBI) score and/or fecal calprotectin level \> 150 ug/gr.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center Coordinator of this site? Confirm its status | Tel Aviv | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.